Clinical Trials Arena on MSN15d
Orca Bio makes a splash as T-cell therapy cuts GvHD in blood cancer patients
Graft versus host disease (GvHD) is a complication from stem cell transplants where the patient recognises the cells as foreign and rejects them.
Medscape12d
Precision T-Cell Therapy Improves Blood Cancer Outcomes
In treating hematologic malignancies, engineered T-cell therapy outperforms standard transplantation with respect to chronic ...
Everyday Health27d
What Is T-Cell Lymphoma?
It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...
BioSpace12d
Adaptimmune Raises ‘Substantial Doubt’ About Business Despite First-in-Class T Cell Therapy
Adaptimmune is rolling out its T cell therapy Tecelra for synovial sarcoma, recording $1.2 million in sales since its ...
FierceBiotech26d
Amgen and CytomX throw off masked T-cell engager, axing asset after assessing data, priorities
Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical data and their pipeline priorities. CytomX signaled the EGFRxCD3 ...